Loading…
Company announces enhanced efficacy in clinical trial.
EnGene Therapeutics Inc. (Nasdaq: ENGN) has reported an improved response rate for its investigational therapy, detalimogene, in the treatment of bladder cancer. The announcement was made following the evaluation of 62 participants in the clinical trial, where a 63% response rate was observed.
This result represents a notable improvement over the previously reported 53% response rate. The trial involved 62 participants, all of whom were part of the evaluation for detalimogene's efficacy in bladder cancer treatment.
As of the latest data, EnGene Therapeutics has a free float of 25,046,600 shares.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.